Kumaraguru Raja
Stock Analyst at Brookline Capital
(0)
# 5046
Out of 5,358 analysts
20
Total ratings
16.67%
Success rate
-30.65%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PALI Palisade Bio | Maintains: Buy | 16 16 | 0.69 | 2218.84% | 2 | May 13, 2025 | |
QNCX Quince Therapeutics | Initiates Coverage On: Buy | 9 | 1.17 | 669.23% | 1 | Dec 18, 2024 | |
SABS SAB Biotherapeutics | Initiates Coverage On: Buy | 8 | 1.81 | 341.99% | 1 | Jun 7, 2024 | |
FBRX Forte Biosciences | Initiates Coverage On: Buy | 100 | 11.32 | 783.39% | 2 | May 30, 2024 | |
HEPA Hepion Pharmaceutica... | Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 150 | 0.58 | 25762.07% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 15 | 4 | 275% | 1 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 9 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 21 | 3.43 | 512.24% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 15 | n/a | n/a | 1 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 90 | 37.95 | 137.15% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 31 | 0.62 | 4900% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 3360 | 0.75 | 447900% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 320 | n/a | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 120 | n/a | n/a | 1 | Mar 25, 2021 |